Head-to-head · Value Score
CoreAge Rx vs Gala Health
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, Gala Health a 75. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameGala Health
#94 · Grade C+ · Fair Price
Est. first month
$149/mo (yearly subscription)
Save ~89% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 75 — an est. $99/mo first month, with no teaser step-up baked in. Gala Health isn't out of it: Tirzepatide-first shoppers in any state who will sign up for a year to hold a low rate, and who value having a brand-name fallback on the same account.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | Gala Health |
|---|---|---|
| Value Score | 93 (A+) | 75 (C+) |
| Est. first month | $99/mo | $149/mo (yearly subscription) |
| Save vs brand-name | ~89% | ~89% |
| Semaglutide | $99/mo | Not disclosed |
| Tirzepatide | $149/mo | $179/mo (yearly subscription) |
| Both molecules | Yes | No |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | All 50 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Gala Health
Some of the lowest compounded-tirzepatide rates in the ranking — but $149 and $179 are both yearly-subscription prices, and Gala publishes no month-to-month rate at all.
Why it's a deal
- $149/mo microdose and $179/mo full dose with all doses included — genuinely low rates if the yearly term suits you
- Available in all 50 states, so the low price isn't gated to a few regions
- Prices are published openly on the site rather than held behind an intake quiz
- Offers an FDA-approved brand-name path (Ozempic) alongside compounded, plus HRT/menopause care on the same platform
The fine print
- $149 and $179 are yearly-subscription rates — no month-to-month price is published anywhere, and the FAQ's shorter-term figure is $199/mo on a 3-month plan
- Compounded medication is not FDA-approved — confirm the 503A/B pharmacy before you buy
- The brand-name option is very expensive at ~$1,299/mo
- No oral/sublingual route yet, and no disclosed compounded semaglutide price
- Newer operator (Gala GLP-1, AI Coaching Inc) with a thin public track record
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to Gala Health.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.